European Journal of Drug Metabolism and Pharmacokinetics

Supplementary Information

Oral pharmacokinetics in beagle dogs of the mitragynine metabolite, 7-hydroxymitragynine

Elizabeth A. Maxwell[1], Tamara I. King[2], Shyam H. Kamble[2,3], Kanumuri Siva Rama Raju[2,3], Erin C. Berthold[2], Francisco León[4], Aidan Hampson[5], Lance R. McMahon[6], Christopher R. McCurdy[2,3,4*], and Abhisheak Sharma[2,3*]

Affiliation

[1]Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA

[2]Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA

[3]Translational Drug Development Core, Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA

[4]Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA

[5]Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA

[5]Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA

Supplementary Table 1. Bench-top stability of 7-hydroxymitragynine in pooled dog plasma with or without protease inhibitor cocktail (N = 5 at each concentration).

Stability Condition	Concentration (ng/ml)	Variation (%Deviation)	
		Pooled dog plasma	Pooled dog plasma spiked with protease cocktail inhibitor
Bench top stability (room temperature, 1 h)	3	-11.8	-7.8
	180	-11.0	-7.4